Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction:
- Share Sale Price: £12.01 per Ordinary share.
- Transaction Date: February 21, 2011.
Material Changes
The filing details the sale of shares by PDMRs to cover tax liabilities following the vesting of awards made in 2008 under the GlaxoSmithKline Share Value Plan. The three-year vesting period for these awards concluded on December 31, 2010. No other material changes to the company's financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports on the compliance notification of share sales in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Four PDMRs (Mr. S M Bicknell, Mr. D S Redfern, Ms. C Thomas, and Mrs. V Whyte) sold shares on February 21, 2011.
- The sales were executed at £12.01 per share to satisfy tax obligations on vested 2008 awards.
- Specific share counts sold and retained were: Mr. Bicknell (1,286 sold, 1,234 retained), Mr. Redfern (1,709 sold, 1,641 retained), Ms. Thomas (1,286 sold, 1,234 retained), and Mrs. Whyte (612 sold, 588 retained).
- This document does not contain quarterly or annual financial performance data.